| (Values in U.S. Thousands) | Jun, 2019 | Jun, 2018 | Jun, 2017 | Jun, 2016 | Jun, 2015 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -8,050 | -11,140 | -8,080 | -8,860 | -4,800 |
| Net Income Growth | +27.74% | -37.87% | +8.80% | -84.58% | -253.85% |
Delmar Pharmaceuticals Inc (DMPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
DelMar Pharmaceuticals, Inc. is involved in developing drug for orphan cancer indications. DelMar Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.